A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Kallyope Inc.
- Study ID
- NCT06848075
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- Elismetrep (K-304) 2 mg — DRUGAdministered orally
- Elismetrep (K-304) 5 mg — DRUGAdministered orally
- Elismetrep (K-304) 10 mg — DRUGAdministered orally
- Elismetrep (K-304) 20 mg — DRUGAdministered orally
- Placebo — DRUGAdministered orally
Study Details
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the acute treatment of migraine.
Key Dates
- First listed
- Feb 26, 2025
- Start date
- Mar 11, 2025
- Status verified
- Aug 2026
- Primary completion
- Aug 4, 2025
- Completion
- Aug 4, 2025
Study Design
- Enrollment
- 431 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Elismetrep (K-304) Dose Level 1Participants received a single dose of elismetrep 2 mg
- Experimental: Elismetrep (K-304) Dose Level 2Participants received a single dose of elismetrep 5 mg
- Experimental: Elismetrep (K-304) Dose Level 3Participants received a single dose of elismetrep 10 mg
- Experimental: Elismetrep (K-304) Dose Level 4Participants received a single dose of elismetrep 20 mg
- Placebo Comparator: PlaceboParticipants received a single dose of elismetrep-matched placebo
Primary Outcome Measure
Pain Freedom [ Time Frame: 2 hours post-dose ]
Locations (66)
Find similar trials in Birmingham, AL
Nationwide
By condition
By specialty
Related Studies
- Quality Improvement and Practice Based Research in Neurology Using the EMRPHASE4 · Enrolling By Invitation · Endeavor Health · Evanston, Illinois
- Pain Biomarker StudyPHASE1 · Enrolling By Invitation · The University of Texas Health Science Center, Houston · Houston, Texas
- Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial PainPHASE2 · Recruiting · Stanford University · Stanford, California
- Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to RimegepantRecruiting · Pfizer · Wilmington, North Carolina